Nordea Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$227M Buy
363,479
+269,157
+285% +$183M 0.19% 125
2026
Q1
$72.4M Sell
94,322
-42,999
-31% -$32.9M 0.07% 232
2025
Q4
$106M Buy
137,321
+74,350
+118% +$50.5M 0.09% 206
2025
Q3
$35.1M Buy
62,971
+15,983
+34% +$9.04M 0.03% 300
2025
Q2
$24.5M Buy
46,988
+2,768
+6% +$1.54M 0.02% 314
2025
Q1
$28M Buy
44,220
+1,553
+4% +$1.07M 0.03% 303
2024
Q4
$30.2M Buy
42,667
+8,135
+24% +$6.83M 0.03% 294
2024
Q3
$36.4M Sell
34,532
-10,729
-24% -$11.9M 0.04% 280
2024
Q2
$47.4M Buy
45,261
+16,066
+55% +$15.6M 0.06% 260
2024
Q1
$28.2M Buy
29,195
+5,495
+23% +$5.23M 0.03% 312
2023
Q4
$20.9M Sell
23,700
-87
-0.4% -$71.6K 0.03% 323
2023
Q3
$19.7M Sell
23,787
-1,364
-5% -$1.07M 0.03% 302
2023
Q2
$17.8M Sell
25,151
-419
-2% -$323K 0.02% 322
2023
Q1
$21M Buy
25,570
+349
+1% +$263K 0.03% 286
2022
Q4
$18M Sell
25,221
-964
-4% -$711K 0.03% 302
2022
Q3
$18.2M Sell
26,185
-6,194
-19% -$3.9M 0.03% 299
2022
Q2
$19M Sell
32,379
-16,491
-34% -$10.7M 0.03% 304
2022
Q1
$34.4M Sell
48,870
-2,206
-4% -$1.4M 0.04% 273
2021
Q4
$32.8M Sell
51,076
-967
-2% -$595K 0.04% 284
2021
Q3
$31.9M Buy
52,043
+1,190
+2% +$739K 0.04% 292
2021
Q2
$28.4M Buy
50,853
+469
+0.9% +$238K 0.04% 299
2021
Q1
$23.8M Buy
50,384
+2,270
+5% +$1.11M 0.03% 303
2020
Q4
$23.2M Buy
48,114
+4,573
+11% +$2.47M 0.04% 290
2020
Q3
$25M Sell
43,541
-365
-0.8% -$221K 0.05% 260
2020
Q2
$27.1M Buy
43,906
+28,313
+182% +$16.1M 0.03% 291
2020
Q1
$7.25M Sell
15,593
-104
-0.7% -$42.9K 0.02% 355
2019
Q4
$5.89M Buy
15,697
+57
+0.4% +$19.2K 0.01% 427
2019
Q3
$4.31M Buy
15,640
+90
+0.6% +$26.6K 0.01% 566
2019
Q2
$4.87M Buy
15,550
+2,164
+16% +$720K 0.01% 488
2019
Q1
$5.49M Buy
13,386
+9,171
+218% +$3.78M 0.01% 524
2018
Q4
$1.57M Hold
4,215
﹤0.01% 883
2018
Q3
$1.7M Buy
4,215
+64
+2% +$24.4K ﹤0.01% 914
2018
Q2
$1.43M Sell
4,151
-20,720
-83% -$6.48M ﹤0.01% 783
2018
Q1
$8.56M Sell
24,871
-760
-3% -$264K 0.02% 338
2017
Q4
$9.64M Sell
25,631
-2,839
-10% -$1.15M 0.02% 301
2017
Q3
$12.7M Sell
28,470
-5,634
-17% -$2.68M 0.03% 259
2017
Q2
$16.8M Sell
34,104
-5,168
-13% -$2.26M 0.04% 219
2017
Q1
$15.2M Buy
39,272
+760
+2% +$282K 0.04% 223
2016
Q4
$14.1M Buy
38,512
+6,162
+19% +$2.34M 0.04% 243
2016
Q3
$13M Sell
32,350
-914
-3% -$367K 0.03% 246
2016
Q2
$11.6M Buy
33,264
+9,480
+40% +$3.65M 0.03% 231
2016
Q1
$8.57M Buy
23,784
+20,857
+713% +$8.59M 0.03% 251
2015
Q4
$1.59M Sell
2,927
-50
-2% -$27.1K 0.01% 458
2015
Q3
$1.39M Buy
2,977
+266
+10% +$143K 0.01% 395
2015
Q2
$1.38M Buy
2,711
+129
+5% +$63K ﹤0.01% 393
2015
Q1
$1.17M Hold
2,582
﹤0.01% 431
2014
Q4
$1.06M Sell
2,582
-499
-16% -$196K ﹤0.01% 470
2014
Q3
$1.11M Sell
3,081
-881
-22% -$295K ﹤0.01% 483
2014
Q2
$1.12M Sell
3,962
-1,496
-27% -$443K ﹤0.01% 534
2014
Q1
$1.64M Sell
5,458
-1,174
-18% -$362K 0.01% 463
2013
Q4
$1.82M Buy
6,632
+392
+6% +$113K 0.01% 452
2013
Q3
$1.95M Hold
6,240
0.01% 439
2013
Q2
$1.4M Buy
+6,240
New +$1.45M 0.01% 510

Other funds holding REGN

Nordea Investment Management's REGN Position: Q2 2026 in Review

Nordea Investment Management increased its Regeneron Pharmaceuticals (REGN) stake by 285% in Q2 2026, buying an estimated $183M and bringing the position to 363,479 shares worth $227M. The position accounts for 0.19% of the portfolio, ranked #125.

Nordea Investment Management first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Nordea Investment Management held 363,479 shares of Regeneron Pharmaceuticals worth $227M as of Q2 2026.
  • Nordea Investment Management bought 269,157 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $183M.
  • Regeneron Pharmaceuticals made up 0.19% of Nordea Investment Management's portfolio in Q2 2026, its #125 holding.
  • Nordea Investment Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Nordea Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.